Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted

Ovarian cancer is the second most common gynaecological malignancy. It usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with poor diagnosis. Despite the chemosensitivity of intraperitoneal chemotherapy, the majority of patients i...

Full description

Saved in:
Bibliographic Details
Published in:Artificial cells, nanomedicine, and biotechnology nanomedicine, and biotechnology, 2019-12, Vol.47 (1), p.4066-4088
Main Authors: Gupta, Swati, Pathak, Yashwant, Gupta, Manish K, Vyas, Suresh P
Format: Article
Language:English
Subjects:
Drug Delivery Systems - methods
Female
Humans
Molecular Targeted Therapy - methods
Nanomedicine - methods
Neoplasm Staging
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - epidemiology
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is the second most common gynaecological malignancy. It usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with poor diagnosis. Despite the chemosensitivity of intraperitoneal chemotherapy, the majority of patients is relapsed and eventually dies. In addition to the challenge of early detection, its treatment presents several challenges like the route of administration, resistance to therapy with recurrence and specific targeting of cancer to reduce cytotoxicity and side effects. In ovarian cancer therapy, nanocarriers help overcome problems of poor aqueous solubility of chemotherapeutic drugs and enhance their delivery to the tumour sites either by passive or active targeting, and thus reducing adverse side effects to the healthy tissues. Moreover, the bioavailability to the tumour site is increased by the enhanced permeability and retention (EPR) mechanism. The present review aims to describe the current conventional treatment with special reference to passively and actively targeted drug delivery systems (DDSs) towards specific receptors designed against ovarian cancer to overcome the drawbacks of conventional delivery. Conclusively, targeted nanocarriers would optimise the intra-tumour distribution, followed by drug delivery into the intracellular compartment. These features may contribute to greater therapeutic effect.
ISSN:2169-141X
DOI:10.1080/21691401.2019.1677680